| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Adopters of Attune's ensoETM proactive esophageal cooling device can use a Bundled Disposable Purchase Option to acquire Gentherm's Blanketrol® III through Attune.
Attune Medical and Gentherm (NASDAQ:THRM), a leader in medical patient temperature management systems, have entered a non-exclusive distribution agreement for healthcare providers in need of proactive esophageal cooling technology. Adopters of Attune's ensoETM thermal regulating device will be provided the opportunity to use a bundled disposable purchase option to acquire Gentherm's Blanketrol III directly from Attune. Attune will also offer customers a 90-day evaluation program for the Blanketrol III.
Attune Medical's ensoETM is a single use thermal regulating device that is placed in the esophagus and connected to an external heat exchange unit such as the Blanketrol III, creating a closed-loop system for heat transfer to increase or decrease patient temperature. Its placement in the esophagus, with proximity to blood flow from the heart and great vessels, allows highly efficient heat transfer. Unlike surface warming devices, ensoETM‘s internal placement doesn't impede patient access during surgery and allows gastric decompression and administration of fluids and medications.
The Blanketrol III is used to lower or to raise a patient's temperature and/or maintain a desired temperature through conductive heat transfer.
"We were happy to take advantage of this distribution option, as it was an attractive route to avoid the need for capital funds and begin treating our high patient volume as quickly as possible," noted Dr. Mayank Sardana, Cardiac Electrophysiologist at HonorHealth in Phoenix, Arizona.
"Gentherm's Blanketrol III System is one of the more popular options to use with the ensoETM, which is experiencing rapid uptake amongst a broad range of clinicians," commented Jay Istvan, Attune's president and CEO. "We are pleased to provide our customers with the convenience of an additional method to obtain a Blanketrol III for use with the ensoETM system which may offer a faster route to provide this therapy."
"The ensoETM is an innovative approach to targeted temperature management and we are pleased that we can collaborate with Attune to provide our reliable and trusted Blanketrol III system to deliver a full-service solution for health care providers," commented Steve Fletcher, Senior Vice President & General Manager, Gentherm Medical.
Posted In: THRM
